1386PD - IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
| Autor: | Reck, M., Wehler, T., Orlandi, F., Nogami, N., Barone, C., Moro-Sibilot, D., Shtivelband, M., González Larriba, J.L., Rothenstein, J., Frueh, M., Shankar, G., Lee, A., Deng, Y., Patel, H., Kelsch, C., Lin, W., Socinski, M.A. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|